BioCentury | May 1, 2020
Regulation

CHMP backs new therapy for 1L AML, triple combos for asthma

...novo or secondary acute myelogenous leukemia (AML) in patients who can’t receive induction chemotherapy. The SMO...
...licensed from Acceleron Pharma Inc. (NASDAQ:XLRN). Targets ACVR2B - Activin receptor type 2B SMO - Smoothened Stephen...
BioCentury | Feb 14, 2020
Product Development

AML’s growing options

...tyrosine kinase 3 IDH1 - Isocitrate dehydrogenase 1 IDH2 - Isocitrate dehydrogenase 2 SMO - Smoothened Stephen...
BioCentury | Aug 8, 2019
Distillery Therapeutics

CDK7 inhibition for drug-resistant cancers

...resistant to SMO inhibitors. A CDK7 inhibitor tool compound decreased viability of cells resistant to SMO...
...CDK7 in tumors or the CDK7 inhibitor decreased tumor growth in a mouse model of SMO...
...OTX015, Y-803) in Phase I testing for hematologic malignancies. TARGET/MARKER/PATHWAY: Cyclin dependent kinase 7 (CDK7); smoothened (SMO)...
BioCentury | Jun 25, 2019
Distillery Therapeutics

Herb-derived flavonoid identified as potential TNBC treatment

...wogonoside, a SMO inhibitor, could help treat triple-negative breast cancer (TNBC), a new indication for SMO...
...binding assays showed the compound's target is SMO, and cell-based assays suggested it promotes ubiquitination-dependent SMO...
...In a xenograft mouse model of TNBC, the compound decreased tumor weight by 55%. Marketed SMO...
BioCentury | Nov 30, 2018
Clinical News

FDA approves two drugs for first-line AML

...Inc. Daiichi Sankyo Co. Ltd. Genentech Inc. Pfizer Inc. Roche B cell lymphoma 2 (BCL-2) (BCL2) FMS-like tyrosine kinase 3 (FLT3) (CD135) Smoothened (SMO)...
BioCentury | Nov 20, 2018
Company News

Leo Pharma invests in PellePharm to develop rare skin disease therapy

...subsidiary of BridgeBio Pharma LLC (Palo Alto, Calif.). Mary Romeo patidegib, saridegib (IPI-926) Leo Pharma A/S PellePharm Inc. BridgeBio Pharma Inc. Smoothened (SMO)...
BioCentury | Jun 29, 2018
Clinical News

FDA grants Priority Review to Pfizer's glasdegib for AML

...hedgehog antagonist. Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Glasdegib (PF-04449913) Business: Cancer Jennie Walters glasdegib (PF-04449913) Pfizer Inc. Smoothened (SMO)...
BioCentury | Apr 4, 2018
Finance

Sofinnova crosses over

Sofinnova Partners raised its first crossover fund to attract international investors to late-stage EU biotechs, with the goal of bringing the best to the U.S. market. On April 4, Sofinnova announced the close of Sofinnova...
BioCentury | Mar 20, 2018
Distillery Therapeutics

Cancer

...or its co-activator MLK1 could help treat drug-resistant BCC. In one human and two mouse SMO...
...SRF decreased proliferation compared with no treatment or scrambled shRNA. In two mouse models of SMO-resistant...
...growth compared with vehicle. Next steps could include testing MLK1 inhibition in models of other SMO...
BioCentury | Sep 29, 2017
Company News

Pfizer, MD Anderson partner for cancer combo clinical trials

...Houston, Texas Business: Cancer Elizabeth S. Eaton 4-1BB agonist Bavencio gemtuzumab ozogamicin glasdegib PF-04518600 Utomilumab Pfizer Inc. University of Texas MD Anderson Cancer Center OX40 PD-L1 Smoothened (SMO)...
Items per page:
1 - 10 of 125